Is there a place for angiotensin receptor‑neprilysin inhibitors in the treatment of heart failure patients after heart transplantation?
Publication details: Mumbai Wolter Kluwer 2019Edition: Vol.51(6), Nov-DecDescription: 413-415pSubject(s): Online resources: In: Indian Journal of PharmacologySummary: We present a case report of a heart failure patient after heart transplantation due to end‑stage ischemic cardiomyopathy with significant clinical and echocardiographic improvement 3 months after the introduction of sacubitril/valsartan, an angiotensin receptor‑neprilysin inhibitor. This new class of drugs is proved to be beneficial in heart failure patients, especially with reduced ejection fraction (HFrEF),but they have not yet been used in heart failure patients after heart transplantation. We believe that the increase of left ventricular systolic function, improvement of global longitudinal strain, and reduction of pulmonary hypertension with consequent clinical recovery in our patient may have been caused by sacubitril/valsartan.| Item type | Current library | Status | Barcode | |
|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2021140 |
We present a case report of a heart failure patient after heart transplantation due to end‑stage ischemic cardiomyopathy with significant clinical and echocardiographic improvement 3 months after the introduction of sacubitril/valsartan, an angiotensin receptor‑neprilysin inhibitor. This new class of drugs is proved to be beneficial in heart failure patients, especially with reduced ejection fraction (HFrEF),but they have not yet been used in heart failure patients after heart transplantation. We believe that the increase of left ventricular systolic function, improvement of global longitudinal strain, and reduction of pulmonary hypertension with consequent clinical recovery in our patient may have been caused by sacubitril/valsartan.
There are no comments on this title.
Click on an image to view it in the image viewer